Form 4: Mirum Pharma COO Radovich Reports Stock Transactions

Mirum Pharmaceuticals' President and COO, Peter Radovich, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
• On January 21, 2026, 4,167 restricted stock units vested and converted into common stock.
• Following the vesting, on January 22, 2026, Radovich sold 2,382 shares of common stock at a price of $93.3252 per share.
• This sale was conducted to cover tax withholding obligations related to the RSU vesting.
• The vesting schedule for the RSUs indicates that 1/3rd vests annually on January 21, starting from January 21, 2025, over a three-year period.
• Radovich's beneficial ownership of common stock after these transactions is 20,679 shares, which includes 222 shares acquired through the Employee Stock Purchase Plan on November 10, 2025.
• He also beneficially owns 8,333 restricted stock units.

Sentiment

Score: 5

Explanation: The transactions represent a routine vesting of equity compensation followed by a sale to cover tax obligations, which is a common practice and does not inherently signal strong positive or negative sentiment regarding the company's future prospects. The executive also acquired shares via ESPP.

Positives

• Vesting of 4,167 restricted stock units, indicating continued equity compensation and retention of a key executive.
• Acquisition of 222 shares through the Employee Stock Purchase Plan on November 10, 2025, demonstrating ongoing investment by the executive.

Negatives

• Sale of 2,382 shares of common stock at $93.3252, reducing direct share ownership, although this was for tax withholding purposes.

Future Outlook

The vesting schedule for the restricted stock units indicates future vesting events on the anniversaries of January 21, 2025, over a three-year period, with the entire award vesting by January 21, 2028.

Industry Context

This filing reflects routine insider equity compensation and tax-related transactions, common across the pharmaceutical industry for executive retention and incentive programs. It does not provide broader insights into Mirum Pharmaceuticals' market position or strategic direction within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even for tax purposes, could be perceived neutrally to slightly negatively, though it is a common practice. The vesting and ESPP acquisition are generally positive for executive alignment.
• Employees: The vesting of RSUs and participation in an ESPP demonstrate the company's ongoing equity compensation programs, which can be positive for employee morale and retention.

Next Steps

• Future vesting of remaining 8,333 restricted stock units on subsequent anniversaries of January 21, 2025, until fully vested on the three-year anniversary.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Peter Radovich, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Employee Stock Purchase Plan